AngioDynamics (ANGO) Reports In-Line Q1 EPS, Offers Q2 and FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Canaccord Genuity Cuts Price Target on AngioDynamics (ANGO) Following 1Q16
October 9, 2015 8:55 AM EDTCanaccord Genuity maintained a Buy rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $17.50 (from $19.00), following the company's 1Q16 earnings results. ANGOs salesforce has now converted approximately 45% of Morpheus customers over to BioFlow, with BioFlow PICC sales up 22% during the quarter.... More
Piper Jaffray Cuts Price target on AngioDynamics (ANGO) Following 1Q16 Results
October 9, 2015 8:12 AM EDTPiper Jaffray maintained a Neutral rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $14.00 (from $18.00), following the company's 1Q16 earnings results. Revenues missed, coming in at $83.7M, and earnings were in line with expectations.
Analyst Thomas Gunderson commented, "ANGO essentially... More
